Ascendis Pharma A/S (ASND) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown
ASND's revenue distribution by segment and geography
By Geography
ASND Revenue Analysis (2014–2025)
As of February 28, 2026, Ascendis Pharma A/S (ASND) generated trailing twelve-month (TTM) revenue of $717.8 million, reflecting explosive growth of +41.0% year-over-year. The most recent quarter (Q4 2025) recorded $245.2 million in revenue, up 14.8% sequentially.
Looking at the longer-term picture, ASND's 5-year compound annual growth rate (CAGR) stands at +150.9%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $691.7 million in 2025, representing a new all-time high.
When compared to Healthcare sector peers including AGIO (+36.3% YoY), VRTX (+10.4% YoY), and BBIO (+126.3% YoY), ASND has underperformed the peer group in terms of revenue growth. Compare ASND vs AGIO →
Peer Comparison
Compare ASND's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ASNDCurrent | $718M | +41.0% | +150.9% | -18.9% | |
| AGIO | $54M | +36.3% | - | -873.9% | |
| VRTX | $12.0B | +10.4% | +14.1% | 39.1% | |
| BBIO | $502M | +126.3% | +127.4% | -113.3% | |
| BMRN | $3.2B | +12.9% | - | 16.6% | |
| PTCT | $1.7B | +97.5% | +35.4% | 50.1% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $691.7M | +90.2% | $588.5M | 85.1% | $-130,892,766 | -18.9% |
| 2024 | $363.6M | +36.3% | $319.4M | 87.8% | $-278,763,000 | -76.7% |
| 2023 | $266.7M | +421.2% | $222.3M | 83.4% | $-455,541,000 | -170.8% |
| 2022 | $51.2M | +557.9% | $39.0M | 76.3% | $-561,814,000 | -1097.9% |
| 2021 | $7.8M | +11.9% | $4.3M | 54.7% | $-451,792,000 | -5808.6% |
| 2020 | $7.0M | -48.0% | $7.0M | 100.0% | $-330,620,000 | -4755.1% |
| 2019 | $13.4M | +26.4% | $13.4M | 100.0% | $-226,719,000 | -1695.1% |
| 2018 | $10.6M | +591.6% | $10.6M | 100.0% | $-154,757,000 | -1462.6% |
| 2017 | $1.5M | -66.8% | $1.5M | 100.0% | $-111,541,000 | -7290.3% |
| 2016 | $4.6M | -43.3% | $4.6M | 100.0% | $-72,920,000 | -1583.2% |
See ASND's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ASND Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare ASND vs AGIO
See how ASND stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is ASND's revenue growth accelerating or slowing?
ASND revenue is accelerating at +41.0% year-over-year, exceeding the 5-year CAGR of +150.9%. TTM revenue reached $718M. Growth momentum has increased versus prior periods.
What is ASND's long-term revenue growth rate?
Ascendis Pharma A/S's 5-year revenue CAGR of +150.9% reflects the sustained expansion pattern. Current YoY growth of +41.0% is above this long-term average.
How is ASND's revenue distributed by segment?
ASND reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.